Hepatology international · 2026
Global trends in metabolic-associated hepatocellular carcinoma: genetic and socio-demographic drivers.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Na, Xiong Xinying, Wang Xinyue, Wei Shuang, Shi Xinyu, Chen Yilin, Zhou Wenjun, Wang Jianying, Zhang Lei, Liu Baocheng, Song Hualing, Yu Huiting, Ji Guang
Аннотация
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a primary driver of hepatocellular carcinoma (HCC). However, the synergistic impact of ancestral genetic susceptibility and socio-demographic transitions on the global MASLD-HCC landscape remains insufficiently quantified.
METHODS: Using GBD 2021 data, we analyzed MASLD-HCC mortality and DALYs across 204 countries (1990-2021). Temporal trends were quantified using Joinpoint-derived average annual percent change (AAPC). We integrated ancestry-weighted risk allele frequencies (RAF) for five high-impact SNPs (PNPLA3, TM6SF2, MBOAT7, GCKR, HSD17B13) into GBD regions and utilized frontier and inequality analyses to evaluate socio-demographic drivers and 2050 projections.
RESULTS: In 2021, sub-Saharan Africa exhibited the highest mortality age-standardized rates (up to 1.09/100,000), while high-income super regions and Southern Latin America showed the most rapid historical increases (AAPC: 2.88% to 4.19%). Genetic-epidemiological mapping revealed that regional mortality burden was strongly correlated with PNPLA3 (ρ = 0.663, p = 0.001) and GCKR (ρ = 0.662, p = 0.001) risk frequencies, while HSD17B13 exerted a protective effect (ρ = -0.562, p = 0.008). The concentration index shifted toward zero (from - 0.0752 to - 0.0459), indicating an epidemiological convergence and global homogenization of the MASLD-HCC epidemic. By 2050, high-income super regions are projected to experience a disproportionate 52.11% surge in mortality, reflecting a significant delayed burden of cumulative metabolic risk exposure.
CONCLUSION: The MASLD-HCC landscape is transitioning toward global prevalence, driven by genetic architecture and metabolic shifts. This narrowing inequality gap and impending mortality surge necessitate genetically-informed precision prevention and re-evaluation of metabolic-oncology surveillance.
METHODS: Using GBD 2021 data, we analyzed MASLD-HCC mortality and DALYs across 204 countries (1990-2021). Temporal trends were quantified using Joinpoint-derived average annual percent change (AAPC). We integrated ancestry-weighted risk allele frequencies (RAF) for five high-impact SNPs (PNPLA3, TM6SF2, MBOAT7, GCKR, HSD17B13) into GBD regions and utilized frontier and inequality analyses to evaluate socio-demographic drivers and 2050 projections.
RESULTS: In 2021, sub-Saharan Africa exhibited the highest mortality age-standardized rates (up to 1.09/100,000), while high-income super regions and Southern Latin America showed the most rapid historical increases (AAPC: 2.88% to 4.19%). Genetic-epidemiological mapping revealed that regional mortality burden was strongly correlated with PNPLA3 (ρ = 0.663, p = 0.001) and GCKR (ρ = 0.662, p = 0.001) risk frequencies, while HSD17B13 exerted a protective effect (ρ = -0.562, p = 0.008). The concentration index shifted toward zero (from - 0.0752 to - 0.0459), indicating an epidemiological convergence and global homogenization of the MASLD-HCC epidemic. By 2050, high-income super regions are projected to experience a disproportionate 52.11% surge in mortality, reflecting a significant delayed burden of cumulative metabolic risk exposure.
CONCLUSION: The MASLD-HCC landscape is transitioning toward global prevalence, driven by genetic architecture and metabolic shifts. This narrowing inequality gap and impending mortality surge necessitate genetically-informed precision prevention and re-evaluation of metabolic-oncology surveillance.